Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, Wegovy curbs appetite — and for most people the reduction is substantial. Semaglutide, the active medicine in Wegovy, activates GLP-1 receptors in the brain's appetite-control centres, lowering hunger signals and increasing the sense of fullness after eating. The STEP 1 trial, published in the New England Journal of Medicine, recorded an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose — a result that would be difficult to achieve without a meaningful change in how hungry participants felt day to day. These are prescription-only medicines; a clinician assesses whether they are appropriate for you before any treatment starts.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial is the clearest reference point. Over 68 weeks, adults taking semaglutide 2.4mg alongside lifestyle changes lost an average of around 15% of their body weight compared with around 2.4% on placebo, a gap that reflects genuine, sustained appetite suppression rather than a short-lived novelty effect. Participants reported eating less, feeling full sooner and (this surprises some people) feeling less preoccupied with food between meals. That last point matters because hunger isn't only about an empty stomach; it also includes the constant mental pull towards eating, which GLP-1 medicines appear to quiet in many people.
The NHS medicines page for semaglutide confirms that the mechanism involves slowing gastric emptying as well as acting centrally on appetite-regulating pathways. Both effects work together: food leaving the stomach more slowly sustains the physical sensation of fullness, while the central action reduces how strongly the brain signals for more food. If you want to understand how and why Wegovy suppresses appetite at a mechanistic level, that detail helps explain why many people on Wegovy describe eating noticeably less without feeling deprived, at least once the treatment reaches the maintenance dose.
It is worth being clear that the titration period, when doses move from 0.25mg up through 0.5mg, 1mg and 1.7mg before reaching 2.4mg, is designed to let the body adjust and limit nausea. Appetite suppression does increase with dose for most people, so the full effect often takes several months to arrive. Expecting dramatic change from the first pen tends to lead to disappointment.
A common misconception is that if Wegovy is working, hunger should disappear entirely. It rarely does. What most people experience is a shift in the baseline: food is less compelling, portions feel satisfying at a smaller size, and skipping a meal or stopping mid-plate becomes easier rather than effortful. For those who do find themselves with a significant loss of appetite on Wegovy, that is a different experience worth understanding separately, because the goal is sustainable eating, not suppression to the point of under-nourishment.
Individual variation is real. Genetics, existing eating patterns, stress, sleep and the dose reached all influence how strongly someone feels the appetite effect. Some people notice a dramatic change within weeks; others find the shift more subtle and gradual. If you are on Wegovy and feel your appetite has not changed much, our page on what to do when Wegovy is not curbing appetite covers the most common reasons and when to discuss them with your prescriber.
Understanding what to eat on Wegovy also matters here. Because portions naturally shrink, protein and fibre become more important per bite, not less. A smaller plate that is nutritionally poor can still leave you more hungry than a smaller plate built around protein and vegetables.
A question our prescribers encounter regularly is whether Wegovy works purely by making people less hungry, or whether something else is going on. The honest answer is both. The primary driver of weight loss is reduced energy intake, which flows from the appetite and satiety effects described above. Some people also ask about what it means to have virtually no appetite on Wegovy, since a reduced pull towards high-calorie, ultra-processed foods is reported in trials and commonly mentioned by patients. Whether this is a direct neurological effect or a consequence of general appetite reduction is still being studied.
For a fuller picture of the medicine itself, our Wegovy treatment overview covers how it is licensed, what the titration schedule looks like and what to expect across the treatment period. If you are also curious about how the appetite effect compares with tirzepatide, our weight-loss treatment overview sets the two medicines alongside each other with the current evidence.
One practical note: the appetite-suppressing effect is strongest when Wegovy is taken consistently each week on the same day. Missed or delayed doses can temporarily reduce the effect. The Patient Information Leaflet (available on the electronic Medicines Compendium) covers what to do if a dose is missed, that decision belongs with your prescriber, not a general guide.
If you are considering Wegovy and want to understand whether it is clinically appropriate for you, start your free consultation with our prescribers, a real clinician reviews every application the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.